RENAL OUTCOMES IN PATIENTS TREATED WITH ANIFROLUMAB FOR SYSTEMIC LUPUS ERYTHEMATOSUS IN THE US: FINDINGS FROM A REAL-WORLD STUDY

PV245 / #126 Poster Topic: AS24 - SLE-Treatment Background/Purpose Renal disease is a common severe manifestation of systemic lupus erythematosus (SLE)[1] and renal function changes dynamically over time.[2] SLE treatment may stabilize renal function from a declining trajectory. Anifrolumab was approved for moderate to severe SLE; however, limited real-world (RW) data is available on renal outcomes after anifrolumab treatment. This analysis investigated the estimated glomerular filtration rate (eGFR) and urine protein-creatinine ratio (UPCR) results in adult patients with SLE before and during anifrolumab treatment. Methods This retrospective, observational cohort study included patients in the American Rheumatology Network (124 rheumatology practices across 27 states). Inclusion criteria: ≥ 18 years of age with SLE diagnosis at anifrolumab initiation (index date), ≥ 180 days of clinical history before index, ≥ 5 anifrolumab infusions in the 180 days post index and anifrolumab adherence during post-index measurements (average < 42 days between infusions), serum creatinine levels < 2.0 mg/dL, UPCR < 2.0 mg/mg, and no other biologic during anifrolumab treatment. Clinical outcomes were assessed for patients with scores at baseline (-180 to -1 days before index), and follow-up (181-360 days post index). Clinical scores (within 28 days after last treatment date) were only included if a patient was on active treatment during assessment. If multiple assessments were made during each period, the one closest to anifrolumab initiation was baseline and the measurement closest to 360 days post initiation was follow-up. Median (IQR) result was reported for each outcome measure. Results Of 169 eligible patients, 92.9% were female, 54.3% were white, and median age was 53.0 (IQR 44.0-63.0) years (Table). Of these patients, 98 had eGFR measures at both baseline and follow-up. Both eGFR measures (median [IQR]) were consistent with normal levels at baseline (93.9, [78.4-106.7] mL/Min/1.73m2) and at follow-up (90.9, [79.5-103.1] mL/Min/1.73m2) (Figure A). At baseline, 54/98 (55.1%), 36/98 (36.7%), and 8/98 (8.2%) patients had eGFR levels > 90 (normal or Stage 1 chronic kidney disease [CKD]), between 60-90 (Stage 2 CKD), and < 60 mL/Min/1.73m2 (Stage 3-5 CKD), respectively. Similarly, at follow-up, 51/98 (52.0%), 36/98 (36.7%), and 11/98 (11.2%) patients had eGFR levels > 90, between 60-90, and < 60 mL/Min/1.73m2, respectively. Median (IQR) UPCR results (n = 24) were 0.14 (0.08-0.19) mg/mg at baseline and 0.08 (0.06-0.25) mg/mg at follow-up (Figure B). Two of the 24 patients with baseline UPCR > 1 mg/mg remained stable (baseline: 1.11 and 1.07 mg/mg, follow-up: 0.44 and 0.72 mg/mg, respectively). Table. Characteristics of Study Population and Subset at Baseline Figure. Boxplots of eGFR (A) and UPC Ratio (B) measures (1 per patient per period) at Baseline and Follow-up (181-360 days). Boxplot represents median (middle line), lower and upper quartile (bottom and top horizontal line). IQR (colored area), and whiskers extend to 1.5 * IQR. Conclusions In this RW study of patients with SLE on anifrolumab, baseline eGFR was within normal range and maintained up to 1 year after treatment initiation. Regardless of baseline proteinuria, UPCR remained stable up to 1 year after anifrolumab initiation. This is consistent with anifrolumab effects on the kidney from the randomized clinical trial.[3] Further RW studies to determine long-term renal outcomes with anifrolumab are underway. References: [1.] Kim Y. J Rheum Dis 2018;25:81-99. [2.] Yip TCF. Lupus 2021;30:15-24. [3.] Furie R. Arthritis Rheumatol 2023;75(suppl 9). Acknowledgments: This study was sponsored by AstraZeneca. Writing assistance was provided by Kelly Hunter, PhD, of JK Associates Inc., part of Avalere Health, and funded by AstraZeneca. Presented at EULAR 2024 and reused with permission of Kyttaris V. Ann Rheum Dis 2024;83:979.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.